52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Abbvie Bioresearch Center
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
Icahn School of Medicine At Mount Sinai
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.
Abbvie
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Cellzome
Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.
Martin-Luther-University Halle-Wittenberg
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Abbott Laboratories
Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds.
Universita Di Salerno
Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases.
University of Auckland
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
Martin-Luther-University Halle-Wittenberg
Identification of potent ITK inhibitors through focused compound library design including structural information.
Nycomed
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Ambit Biosciences
Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Chulalongkorn University
Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.
University of Auckland
Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors.
Zhejiang University
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.
University of Auckland
Discovery of pyrrolo[2,3-d]pyrimidine-based molecules as a Wee1 inhibitor template.
Capital Medical University
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Repare Therapeutics
Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential.
West China Hospital
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Hubei Polytechnic University
Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.
University of Auckland
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
University of Connecticut
Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.
Zhejiang University
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.
Zentalis Pharmaceuticals
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Chinese Academy of Sciences
Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics.
Usona Institute
Synthetic Lethality through the Lens of Medicinal Chemistry.
Istituto Italiano Di Tecnologia
A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation.
University of North Carolina At Chapel Hill
Investigation of biaryl heterocycles as inhibitors of Wee1 kinase.
Global Pharmaceutical Research and Development
Identification of an indol-based multi-target kinase inhibitor through phenotype screening and target fishing using inverse virtual screening approach.
University of Naples Federico Ii
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University of Florida
Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.
Martin-Luther-University Halle-Wittenberg
Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
Martin-Luther-University Halle-Wittenberg
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
Moffitt Cancer Center
Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang)
INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP)
Formatherapeutics
Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses
Reata Pharmaceuticals
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
Genentech
Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
Bristol-Myers Squibb
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
University of Tennessee Research Foundation
Materials and method for inhibiting replication protein A and uses thereof
Indiana University Research and Technology